CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo

VM Miller, RF Nelson, CM Gouvion… - Journal of …, 2005 - Soc Neuroscience
VM Miller, RF Nelson, CM Gouvion, A Williams, E Rodriguez-Lebron, SQ Harper
Journal of Neuroscience, 2005Soc Neuroscience
Huntington's disease (HD) and other polyglutamine (polyQ) neurodegenerative diseases
are characterized by neuronal accumulation of the disease protein, suggesting that the
cellular ability to handle abnormal proteins is compromised. As both a cochaperone and
ubiquitin ligase, the C-terminal Hsp70 (heat shock protein 70)-interacting protein (CHIP)
links the two major arms of protein quality control, molecular chaperones, and the ubiquitin-
proteasome system. Here, we demonstrate that CHIP suppresses polyQ aggregation and …
Huntington's disease (HD) and other polyglutamine (polyQ) neurodegenerative diseases are characterized by neuronal accumulation of the disease protein, suggesting that the cellular ability to handle abnormal proteins is compromised. As both a cochaperone and ubiquitin ligase, the C-terminal Hsp70 (heat shock protein 70)-interacting protein (CHIP) links the two major arms of protein quality control, molecular chaperones, and the ubiquitin-proteasome system. Here, we demonstrate that CHIP suppresses polyQ aggregation and toxicity in transfected cell lines, primary neurons, and a novel zebrafish model of disease. Suppression by CHIP requires its cochaperone function, suggesting that CHIP acts to facilitate the solubility of mutant polyQ proteins through its interactions with chaperones. Conversely, HD transgenic mice that are haploinsufficient for CHIP display a markedly accelerated disease phenotype. We conclude that CHIP is a critical mediator of the neuronal response to misfolded polyQ protein and represents a potential therapeutic target in this important class of neurodegenerative diseases.
Soc Neuroscience